-
Juve notch second straight win, Fiorentina's centenary party falls flat
-
US deports right-wing provocateur Milo Yiannopoulos
-
Rybakina eases injury fears ahead of US Open
-
Niger junta says it is back in control after soldiers' mutiny
-
Djokovic kicks off latest Grand Slam quest under US Open lights
-
Erasmus calls Rennie barbs over Springbok scrumming 'nonsense'
-
'Sorry' De Zerbi won't panic after Spurs shambles
-
Lawrence's fifty leaves Pakistan facing record chase to level England series
-
UN, Nepal warn of climate threat after deadly floods
-
Netanyahu condemns settler attack in flashpoint West Bank village
-
USTA boss says structure of new player council not yet set
-
Munoz saves Iraola in Liverpool draw, big-spending Spurs lose again
-
Tiny Elversberg stun Leverkusen on Bundesliga debut, Dortmund beat Hamburg
-
Newcastle condemn dismal Spurs to second successive defeat
-
Tambaram civic groups seek action on eight long-pending issues
-
Tamil Nadu goalball team’s national silver highlights need for wider support
-
Chennai councillors unite across parties to demand ward development funds
-
Tamil Nadu and NUS agree to expand postgraduate and research links
-
Court orders JIPMER assessment of Durai Dayanidhi before money-laundering trial
-
India and China have not named two new border meeting sites
-
French campaign sharpens as far right accuses left over civil disobedience calls
-
Kolkata police register new FIR against Mamata Banerjee over rally timing
-
About 50 Karnataka travellers return from Nepal as 24 remain missing
-
Andhra Pradesh Speaker seeks stronger sports quota and school facilities
-
Cyberabad civic body demolishes 19 unauthorised structures
-
Chembur man held over alleged poisoning of woman’s soft drink
-
Chinchpoklicha Chintamani begins 2026 arrival procession in Parel
-
BMC rejects negligence claims in three Rajawadi Hospital maternity cases
-
Ankle ligament tear ends Neeraj Chopra’s 2026 season
-
Dolly Parton’s Imagination Library leaves global children’s reading legacy
-
Thirty-seven Mumbai pilgrims return after Nepal flood disruption
-
Family searches for Boston engineer missing after Nepal-Tibet floods
-
Baladi Map app turns Lebanon’s local problems into a public record
-
Police appeal for footage after life-threatening Stratford assault
-
James Cleverly leaves shadow cabinet to seek London mayoralty
-
Rural Tamil Nadu students present 64 technology projects at IIT-M research park
-
Three Texas Tech softball players hurt in jet ski collision
-
Matt Leinart assesses Arch Manning and the leading names in college football
-
Felony assaults on older New Yorkers rise sharply, police data show
-
Los Angeles triplets weigh 19.3 pounds in unusually heavy birth
-
New finds strengthen case for Bethsaida at Sea of Galilee site
-
Editorial questions Letitia James’ record as New York attorney general
-
Five college football games that could shape the 2026 season
-
In London, son's agonising wait for news of parents missing in Nepal-Tibet floods
-
Norway's King Haakon VIII pays tribute to late father in first speech
-
Ivory Coast captain Kessie snubs Juventus to rejoin Atalanta
-
South Africa survive onslaught to beat New Zealand and level series
-
Strasbourg fight back to beat Lens in Ligue 1
-
Bryan Kohberger Seeks Judge’s Removal From Post-Conviction Case
-
Study Examines Why Women Have Consensual Sex Without Initial Desire
The scientist rewriting DNA, and the future of medicine
A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.
A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.
He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.
He will receive $3 million for his work on "base editing" and "prime editing," and plans to donate most of it to support his charitable foundation.
"The ability to change a DNA sequence of our choosing into a new sequence of our choosing is a fundamentally very powerful capability," the 51-year-old said, foreseeing uses not just in human medicine but areas like developing more nutritious or disease-resistant crops.
- Correcting the code -
DNA is made up of four chemical "letters" -- the nucleotide bases A, G, T and C. Mutations in this sequence cause thousands of human diseases, yet until recently, gene editing could only fix a limited number of them.
Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations.
It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct genes, while the process can introduce new errors.
"Being able to use genome editing to treat genetic diseases requires, in most cases, ways to correct a DNA misspelling, not simply to disrupt a gene," Liu said.
That insight led his lab to develop base editing, which uses the Cas9 protein -- disabled so it can no longer cut both DNA strands -- to find a target DNA sequence and another enzyme to convert one letter to another -- for example, C to T or G to A.
Reversing the change -- from T to C or A to G -- was tougher. Liu's team overcame the challenge by engineering entirely new enzymes.
These base editors can now correct about 30 percent of the mutations that cause genetic diseases. The technology is already in at least 14 clinical trials.
In one of them, Beam Therapeutics -- which Liu co-founded -- announced it had treated patients of AATD, a rare genetic disorder affecting the lungs and liver, with a single drug infusion.
While traditional gene therapies often disrupt faulty genes or work around them, base editing repairs the mutation itself.
"This was the first time that humans have corrected a mutation that causes a genetic disease in a patient," Liu said.
- Cystic fibrosis hope -
Base editing, quickly dubbed "CRISPR 2.0," can't fix every mutation.
About 70 percent of the roughly 100,000 known disease-causing mutations remain out of its reach, including those caused by missing or extra letters.
To expand the toolkit, Liu's lab introduced prime editing in 2019 -- a method capable of replacing entire sections of faulty DNA with corrected sequences.
If CRISPR is like scissors that cut DNA, and base editors are like using a pencil to correct individual letters, then prime editing is the equivalent of a word processor's "find and replace" function.
Creating this tool required a series of breakthroughs Liu's team describes as "small miracles." The result is, he said, "the most versatile way we know of to edit the human genome."
Among the targets Liu and his team have already pursued with prime editing: cystic fibrosis, a common genetic disease usually caused by three missing DNA letters that causes thick mucus buildup in the lungs and digestive system.
Liu's lab has made much of its work freely accessible, sharing DNA blueprints through a nonprofit library used by tens of thousands of labs worldwide.
"The science we create -- which is ultimately funded by society, through governments and donors -- ultimately goes back to benefit society."
This year's Breakthrough Prize awards come at a fraught moment for US science, as President Donald Trump's government strips funding for institutions like the National Institutes of Health (NIH).
"The NIH is a treasure, not just for this country but for the world," said Liu. "Trying to dismantle the heart of what supports science in this country is like burning your seed corn."
N.AbuHussein--SF-PST